Trial Profile
A phase II study of aroplatin [L-NDDP; Aronex Pharmaceuticals] in subjects with recurrent, unresectable and metastatic colorectal cancer refractory to 5-fluorouracil (F-FU)/leucovorin or capecitabine, and irinotecan
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2005
Price :
$35
*
At a glance
- Drugs L NDDP (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 24 Sep 2005 New trial record.